WallStreetZen

NYSE: GSK
Glaxosmithkline Plc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GSK

Based on 4 analysts offering 12 month price targets for Glaxosmithkline Plc.
Min Forecast
$41.50+8.19%
Avg Forecast
$47.63+24.15%
Max Forecast
$53.00+38.16%

Should I buy or sell GSK stock?

Buy
Strong Buy
3 analysts 42.86%
Buy
0 analysts 0%
Hold
4 analysts 57.14%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is GSK forecast to generate an efficient return?
Company
131.55%
Industry
75.54%
Market
61.82%
GSK's Return on Equity is forecast to be high in 4 years (131.55%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is GSK forecast to generate an efficient return on assets?
Company
18.83%
Industry
16.98%
Market
19.68%
GSK is forecast to generate higher Return on Assets (18.83%) than the US Drug Manufacturers - General industry average (16.98%)
Forecast

GSK earnings per share forecast

What is GSK's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$3.09+25.05%
Avg 2 year Forecast
$3.28+32.54%
Avg 3 year Forecast
$3.32+34.16%
GSK's earnings are forecast to grow at a rate of 10.77% per year, which is not exceptional
Forecast

GSK revenue forecast

What is GSK's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$45.9B+3.46%
Avg 2 year Forecast
$48.0B+8.15%
Avg 3 year Forecast
$49.3B+11.07%
GSK's revenue is forecast to grow at a rate of 3.69% per year, which is not exceptional
Forecast

GSK earnings growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
10.77%
Industry
25.04%
Market
20.34%
GSK's earnings are forecast to grow slower (10.77% per year) than the US Drug Manufacturers - General industry average (25.04%)
Forecast
GSK's earnings are forecast to grow slower (10.77% per year) than the US market average (20.34%)
Forecast
GSK's earnings are forecast to grow faster (10.77% per year) than the risk-free savings rate (1.1%)
Forecast

GSK revenue growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
3.69%
Industry
6.45%
Market
14.82%
GSK's revenues are forecast to grow slower (3.69% per year) than the US Drug Manufacturers - General industry average (6.45%)
Forecast
GSK's revenues are forecast to grow slower (3.69% per year) than the US market average (14.82%)
Forecast

Glaxosmithkline Stock Forecast FAQ

Is Glaxosmithkline Stock a good buy in 2019, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NYSE: GSK) stock is to Buy GSK stock.

Out of 7 analysts, 3 (42.86%) are recommending GSK as a Strong Buy, 0 (0%) are recommending GSK as a Buy, 4 (57.14%) are recommending GSK as a Hold, 0 (0%) are recommending GSK as a Sell, and 0 (0%) are recommending GSK as a Strong Sell.

What is GSK's Price Target?

According to 4 Wall Street analysts that have issued a 1 year GSK price target, the average GSK price target is $47.63, with the highest GSK stock price forecast at $53.00 and the lowest GSK stock price forecast at $41.50.

On average, Wall Street analysts predict that Glaxosmithkline's share price could reach $47.63 by Jan 20, 2022. The average Glaxosmithkline stock price prediction forecasts a potential upside of 24.15% from the current GSK share price of $38.36.

What is GSK's earnings growth forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's forecast annual earnings growth rate of 10.77% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.34%.

Glaxosmithkline's earnings in 2019 is $6,111,842,105.On average, 6 Wall Street analysts forecast GSK's earnings for 2021 to be $16,621,318,958, with the lowest GSK earnings forecast at $15,706,877,462, and the highest GSK earnings forecast at $18,181,248,569. On average, 4 Wall Street analysts forecast GSK's earnings for 2022 to be $17,616,446,469, with the lowest GSK earnings forecast at $16,836,481,663, and the highest GSK earnings forecast at $18,880,527,360.

In 2023, GSK is forecast to generate $17,831,609,174 in earnings, with the lowest earnings forecast at $17,428,179,102 and the highest earnings forecast at $18,235,039,245.

What is GSK's revenue growth forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's forecast annual revenue growth rate of 3.69% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.82%.

Glaxosmithkline's revenue in 2019 is $44,413,157,895.On average, 3 Wall Street analysts forecast GSK's revenue for 2021 to be $247,155,640,232,439, with the lowest GSK revenue forecast at $241,859,555,484,674, and the highest GSK revenue forecast at $251,154,154,013,536. On average, 3 Wall Street analysts forecast GSK's revenue for 2022 to be $258,379,726,455,233, with the lowest GSK revenue forecast at $251,328,866,129,964, and the highest GSK revenue forecast at $262,490,162,496,383.

In 2023, GSK is forecast to generate $265,354,919,436,235 in revenue, with the lowest revenue forecast at $259,447,492,894,867 and the highest revenue forecast at $271,262,345,977,602.

What is GSK's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's current Earnings Per Share (EPS) is $2.47. On average, analysts forecast that GSK's EPS will be $3.09 for 2021, with the lowest EPS forecast at $2.92, and the highest EPS forecast at $3.38. On average, analysts forecast that GSK's EPS will be $3.28 for 2022, with the lowest EPS forecast at $3.13, and the highest EPS forecast at $3.51. In 2023, GSK's EPS is forecast to hit $3.32 (min: $3.24, max: $3.39).

What is GSK's forecast return on equity (ROE) for 2021-2024?

(NYSE: GSK) forecast ROE is 131.55%, which is considered strong.

What is GSK's forecast return on assets (ROA) for 2021-2024?

(NYSE: GSK) forecast ROA is 18.83%, which is higher than the forecast US Drug Manufacturers - General industry average of 16.98%.
WallStreetZen
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatistics
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics